TechInvest News

ECS Botanics launches Vapes and Pastilles - TechInvest Magazine Online

Written by Staff Writers | Nov 14, 2023 9:55:00 AM

Australian medicinal cannabis cultivator and manufacturer ECS Botanics Holdings Ltd (ASX: ECS) has launched a range of GMP-certified cannabidiol (CBD) and tetrahydrocannabinol (THC) pastilles and THC vapes.

The pastilles are available in both CBD and THC forms, as well as combinations of both. The white- label range is sugar-free, plant-based, and is offered in a range of flavours and colours. Pastilles are chewed and dissolved in the mouth, enabling the active ingredients to rapidly enter the bloodstream.

ECS is also launching a white-label THC distillate vape infused with additional terpenes. Australian Made, the vape cartridges use oil concentrates derived from ECS’ pharmaceutical-grade extracts derived from the company’s Australian-grown flower, packaged in child-resistant packaging. The cartridges will be available in 0.5 and 1-mL.

This new THC distillate vape infused with additional terpenes replaces the previous dried flower vaporiser cartridge product that ECS was looking to introduce to the market in 2023.

Products are expected to be in the market before the end of this quarter and will increase the ECS Botanics white-label offering to a range of four products -flowers, oils, pastilles and vapes.

The expansion of our B2B product range to include GMP-certified CBD and THC pastilles and THC vapes provides our customers and their patients with alternative dosage methods. These products are manufactured under stringent pharmaceutical-grade GMP standards that meet all TGA quality and compliance requirements to manufacture pharmaceutical-grade cannabinoid products,” Managing Director, Nan-Maree Schoerie, said.

“Pastilles and vapes are relatively new delivery methods in the Australian market and will provide local patients with advanced treatment options. These innovative product ranges complement our existing B2B offering, leveraging our expertise to meet growing consumer demand for premium medicinal cannabis solutions. We have already received pre-orders for these new products and expect demand to increase rapidly.”